Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men

Source: https://dailynews.ascopubs.org/do/10.1200/ADN.22.200920/full/
Lucio Gordan MD

MACE risk following ADT initiation was higher for older patients compared with younger patients. All comparisons were significant with a P value of < 0.05.

FCS medical oncologist Dr. Lucio Gordan is the lead investigator of this study utilizing data from more than 44,000 patients which demonstrate that the overall risk of major adverse cardiovascular events (MACE) is low in men with prostate cancer treated with androgen deprivation therapy (ADT).

KEY POINTS

  • Electronic medical records from more than 44,000 patients demonstrate that the overall risk of major adverse cardiovascular events (MACE) is low in men with prostate cancer treated with androgen deprivation therapy (ADT).
  • The risk of MACE is higher in older men with prostate cancer treated with ADT compared with younger men.
  • The overall MACE risk was similar at both 1 and 7 years after ADT initiation.

The risk of major adverse cardiovascular events (MACE) following the initiation of androgen deprivation therapy (ADT) in men with prostate cancer is higher for older men compared with their younger counterparts. However, the overall MACE risk at 1 year in all age groups starting ADT is 1% or less, which is much lower than previously published reports. The findings, gleaned from analyses of U.S. electronic medical records, were presented during the virtual National Comprehensive Cancer Network 2022 Annual Meeting.

1 thought on “Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men”

  1. A large retrospective VA study presented at ASCO 2020 reported increased MACE and more so with Agonists than antagonists. So I am skeptical about this EMR review data and it dose not differentiate Agonist vs antagonist; For patients with pre-existing or high risk I choose direct antagonists than agonists. Also to be noted there are increasing data that Abiratarone is associated with increase cardiovascular events.

Leave a Comment

Your email address will not be published.

Related Articles